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Abstract
Background:  Arsenic trioxide (As2O3) exhibits promising anticarcinogenic activity in acute
promyelocytic leukemic patients and induces apoptosis in various tumor cells in vitro. Here, we investigated
the effect of the natural alkaloid berberine on As2O3-mediated inhibition of cancer cell migration using rat
and human glioma cell lines.
Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to
determine the viability of rat C6 and human U-87 glioma cells after treatment with As2O3 or berberine,
and after co-treatment with As2O3 and berberine. The wound scratch and Boyden chamber assays were
applied to determine the effect of As2O3 and berberine on the migration capacity and invasiveness of
glioma cancer cells. Zymography and Western blot analyses provided information on the effect of As2O3
and berberine on the intracellular translocation and activation of protein kinase C (PKC), and some PKC-
related downstream factors. Most assays were performed three times, independently, and data were
analyzed using ANOVA.
Results: The cell viability studies demonstrated that berberine enhances As2O3-mediated inhibition of
glioma cell growth after 24 h incubation. Untreated control cells formed a confluent layer, the formation
of which was inhibited upon incubation with 5 µM As2O3. The latter effect was even more pronounced in
the presence of 10 µM berberine. The As2O3-mediated reduction in motility and invasion of glioma cells
was enhanced upon co-treatment with berberine. Furthermore, it has been reported that PKC isoforms
influence the morphology of the actin cytoskeleton, as well as the activation of metalloproteases MT1-
MMP and MMP-2, reported to be involved in cancer cell migration. Treatment of glioma cells with As2O3
and berberine significantly decreased the activation of PKC α and ε and led to actin cytoskeleton
rearrangements. The levels of two downstream transcription factors, myc and jun, and MT1-MMP and
MMP-2 were also significantly reduced.
Conclusion: Upon co-treatment of glioma cells with As2O3 and berberine, cancer cell metastasis can be
significantly inhibited, most likely by blocking the PKC-mediated signaling pathway involved in cancer cell
migration. This study is potentially interesting for the development of novel chemotherapeutic approaches
in the treatment of malignant gliomas and cancer development in general.
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Background
Arsenic trioxide (As2O3) can effectively induce apoptosis
in acute promyelocytic leukemia (APL) cells in vitro and in
vivo [1-4] and was approved by the United States Food
and Drug Administration in 2000 for the treatment of
patients with relapsed/refractory APL. Although As2O3 has
been evaluated in clinical studies for the treatment of
acute myelogenous leukemia, myelodysplastic syndrome,
and multiple myeloma [5], the diverse sensitivities of dif-
ferent types of tumor cells to this drug limits its clinical
application in a wider spectrum of hematological and,
especially, solid malignancies [6-12]. The antiprolifera-
tion mechanisms of As2O3 in solid tumors are not well
known, and studies on the anti-invasive effects are rare
[13]. Most recently, As2O3 was reported to induce apopto-
sis in a human neuroblastoma cell line via the upregula-
tion of caspase 3 [14]. Paradoxically, arsenic compounds
are well-known human carcinogens that may cause, at rel-
atively high concentrations and/or exposures times [15],
tumors in a variety of human tissues including skin, liver,
and kidneys [10].
The poor prognosis of human malignant gliomas is due to
their invasion and recurrence. The invasion of glioma into
normal brain tissue is a major challenge to clinical inter-
vention because these tumors often highly infiltrate the
surrounding brain tissues. An important characteristic of
high-grade central nervous system tumors is the presence
of massively upregulated protein kinase C (PKC) when
compared to normal glia [16,17]. PKC represents a family
of lipid-dependent serine/threonine kinases that consist
of at least 12 mammalian isoforms divided into three sub-
families including conventional or classic PKCs (cPKC),
non-classic or novel PKCs (nPKC), and atypical PKCs
[18]. The activation of most PKC isoforms depends on the
translocation from the cytosol to subcellular compart-
ments such as the cell membrane [19]. The enhanced PKC
levels in glioma cells have been suggested to be critical to
the hyper-proliferative state and the resistance to apopto-
sis as well as glioma invasion [20,21]. Indeed, treatment
of the human glioblastoma cell line T98G with hypericin
results in a significant inhibition of the cell invasion, an
effect that is also obtained using specific PKC inhibitors
[22], and a high level of PKCα expression in a human
colon-adenocarcinoma cell line has been correlated with
high migratory activity of colon carcinoma cells [23].
Consequently, specific PKC inhibition is thought to con-
trol tumor growth and development [18,24]. PKCα/β
inhibitor Go6976 blocks the invasion of urinary bladder
carcinoma cells [25] and PKC antisense oligonucleotide
LY900003 is in clinical development as a drug against
breast cancer to be used in concert with, for instance,
chemotherapy [26].
Tumor invasion including that of high-grade malignant
gliomas is, for a significant part, mediated by the overpro-
duction of a number of tissue-digesting matrix metallo-
proteinases (MMPs) such as MMP-2 (type IV collagenase
or gelatinase A) and their activators such as membrane-
type 1 metalloproteinase (MT1-MMP) [27,28]. Inhibition
of MMP-2 in human glioma cell line U-87 results in a dra-
matic reduction in cell invasion [29], and induction of
PKC activation in a D54 human glioblastoma cell line
results in enhanced invasion through the activation of
several metalloproteases including MMP-2 [30].
Berberine, a natural alkaloid, has been extensively studied
and shown to exhibit multiple pharmacological activities
such as anti-bacterial [31], anti-oxidative [32], and anti-
cancer and anti-inflammation capabilities [32-34]. Ber-
berine also sensitizes human glioma cells to ionizing radi-
ation in vitro [35]. Recently, berberine has been shown to
exert anti-metastatic properties in non-small lung cancer
cells [36], to be cytotoxic to human tumor U937 and
murine melanoma B16 cells [37], and to inhibit growth
and induce G1 cell cycle arrest followed by apoptosis in
human epidermoid carcinoma A431 cells [38].
Although treatment with As2O3 induces clinical remission
in patients with APL without severe toxicity, relapse with
As2O3-resistant cells still occurs [39] and, in addition,
As2O3 remains a toxic compound at relatively high con-
centrations or exposures [15]. Thus, alternative strategies
that would enhance cellular sensitivity to As2O3, thereby
lowering its concentration of action, would be helpful. In
the present study, we report for the first time that berber-
ine enhances the antiproliferation activity of As2O3 in rat
glioma and human malignant glioma cell lines. In addi-
tion, we investigated As2O3-mediated suppression of gli-
oma cell invasion which likely involves PKC signaling,
ERK phosphorylation, and MMP-2 activation. Thus, this
study may have important clinical applications in the
design of strategies to treat human glioma.
Methods
Cell culture
The rat C6 glioma cell line was originally derived from a
N-nitrosomethylurea-induced rat brain tumor [40]. C6 rat
cancer cells and U-87 human malignant glioma cells were
cultured in minimal essential medium and RPMI (Gibco,
Carlsbad, California) supplemented with 10% fetal calf
serum (Gibco) and antibiotics (100 units/ml penicillin
and 100 µg/ml streptomycin) at 37°C in a humidified
atmosphere composed of 5% CO2 and 95% air. All exper-
iments were performed in plastic tissue culture flasks,
dishes, or in microplates (Nunc, Naperville, Denmark).BMC Cancer 2008, 8:58 http://www.biomedcentral.com/1471-2407/8/58
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Chemical reagents and antibodies
As2O3 was obtained from TTY Biopharm (Taipei, Taiwan).
Berberine, gelatin, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) were purchased
from Sigma-Aldrich (St. Louis, Missouri). Anti-phospho-
p44/42 MAPK and horseradish peroxidase-linked anti-
rabbit or mouse IgG were from Cell Signaling Technology
(Beverly, Massachusetts). Anti-MT1-MMP1, MMP-2, and
PKCs α and ε were purchased from Santa Cruz Biotech-
nology (Santa Cruz, California). Monoclonal anti-orni-
thine decarboxylase (ODC) antibody was purchased from
Sigma-Aldrich.
Cell growth and proliferation assay
Cell viability was determined using the MTT quantitative
colorimetric assay [41]. The cells were seeded at 5 × 104
cells/ml density and incubated with berberine or As2O3 at
various concentrations (0, 1, 2, 5, 10, and 20 µM) for 24
h. Thereafter, the medium was changed and cells were
incubated with MTT (0.5 mg/ml) for 4 h. The viable cell
number is directly proportional to the production of for-
mazan, which can be measured spectrophotometrically (λ
= 563 nm) upon solubilization with isopropanol. Cell
growth was determined by counting the number of cells at
indicated periods of time using a Coulter counter and
measured using the trypan blue (0.2%) exclusion assay
[42].
Boyden chamber assay
The Boyden chamber assay used for the analysis of tumor
cell migration is based on a chamber with two medium-
filled compartments. C6 and U-87 glioma cells were
allowed to grow as discrete colonies and treated with
As2O3 or berberine as described above. Cells were col-
lected by trypsinization and suspended in serum-free
medium at 1 × 105/ml. Migration assays were carried out
in a 48-well chemotaxis chamber (Neuro-Probe, Gaithers-
burg, Maryland). The medium containing 10% fetal calf
serum was added to the lower chamber. The lower and
upper chambers were separated by an 8 µm pore size poly-
carbonate membrane (Poretics, Livermore, California).
Cells were allowed to migrate for 24 h at 37°C in a
humidified atmosphere containing 5% CO2. The mem-
brane was fixed in methanol for 10 min and stained with
modified Giemsa stain (Sigma-Aldrich) for 1 h. Cells on
the upper side of the membrane were removed by cotton
swabs. Cells on the lower side of the membrane were
counted using a light microscope at 200× magnification.
The number of cells that migrated to the lower side of the
membrane was determined [36].
Matrigel invasion assay
Rat C6 and human U87 glioma cells were incubated with
Dulbecco's modified Eagle's medium (DMEM) in 10%
fetal calf serum and then collected by trypsinization. Cells
(1 × 105/ml) in serum-free medium were added to an
inner cup of the 48-well Transwell chamber (Corning Life
Sciences, Corning, New York) that had been coated with
50 µl of Matrigel (BD Biosciences, Franklin Lakes, New
Jersey; 1:10 dilution in serum-free medium). Medium
supplemented with 10% serum or indicated agent was
added to the outer cup. After 24 h, cells that had migrated
through the Matrigel and the 8 µm pore size membrane
were fixed, stained, and counted under a light microscope.
Each experiment was performed in triplicate.
Scratch assays
Scratch assays were performed by plating cells in 6-well
culture dish. After C6 glioma cells were allowed to attach
and reach confluence, a scratch (4 mm) was made
through the culture dish. The cells were washed twice with
phosphate-buffered saline (PBS, pH = 7) before their sub-
sequent incubation with culture medium in the absence
(control) or presence of As2O3 or combinations at appro-
priate concentrations. Photographs of treated cells mov-
ing within the scratch were taken at the indicated time
points. Openlab v3.0.2 image analysis software (Improvi-
sion, Coventry, United Kingdom) was used to quantify
the area progressively filled with cells over the period of
the experiment.
Preparation of total cell extracts and immunoblot analysis
Cellular lysates were prepared by suspending 1 × 106 cells
in 200 µl of lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1
mM sodium orthovanadate, 15 mM MgCl2, 0.1% Triton
X-100, 25 mM MOPS, 100 µM phenylmethylsulfonyl flu-
oride and 20 µM leupeptin, adjusted to pH 7.2). The cells
were disrupted by sonication and extracted at 4°C for 30
min. The supernatant was quantitated using the Pierce
BCA protein quantitation assay (Pierce, Rockford, Illi-
nois) and were electrotransferred to Immobilon-P mem-
branes (Millipore, Bedford, Massachusetts). Detection of
specific proteins was carried out with an enhanced chem-
oluminescence Western blot kit [43].
Immunofluorescent staining assay
One day after plating on coverslips, the cells were treated
with empty vehicle or indicated agent for appropriate
times. Following the treatment period, the cells were fixed
in 2% formaldehyde in PBS for 10 min. The cells were
then permeabelized in PBS containing 1% bovine serum
albumin and 0.1% Triton X-100 for 10 min. The cells were
then incubated for 1 h with rabbit anti-F-actin (Abcam,
Cambridge, Massachusetts), washed in PBS, and incu-
bated for 1 h with anti-rabbit tetramethylrhodamine iso-
thiocyanate (TRITC) labeled secondary antibodies
(Molecular Probes, Carlsbad, California). Following three
additional washes, the coverslips were mounted on glass
slides in anti-fade medium. The images were then col-BMC Cancer 2008, 8:58 http://www.biomedcentral.com/1471-2407/8/58
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lected using fluorescence microscopy (Carl Zeiss, Oberko-
chen, Germany).
PKC translocation assay
Cells were washed twice with PBS and lysed by suspension
in 0.5 ml (2 × 106 cells) of ice-cold homogenization buffer
(20 mM Tris· HCl [pH 7.5], 2 mM EDTA, 2 mM EGTA, 6
mM DTT, 50 µg/ml aprotinin, 48 µg/ml leupeptin, 5
µmol/l pepstatin A, 1 mM phenylmethylsulfonyl fluo-
ride). The homogenate was sonicated and then centri-
fuged for 10 min at 500 × g. The supernatant was
centrifuged at 100,000 × g for 1 h at 4°C. The resulting
supernatant was designated as the soluble (cytosol) frac-
tion. The pellet was solubilized in 200 µl of homogeniza-
tion buffer containing 1% Triton X-100 and centrifuged at
15,000 × g for 15 min at 4°C. The supernatant was desig-
nated as the particulate (membrane) fraction. All extrac-
tion procedures were performed at 4°C. The protein
concentration in cell fractions was determined using a
commercial protein assay (Bio-Rad, Hercules, California)
with bovine serum albumin (BSA) as a standard. Extrac-
tions for immunoblotting were based on previously
described methods.
Zymography
MMP-2 and MMP-9 enzymatic activities were assayed by
gelatin zymography with some modifications. Culture
supernatants were diluted 4:1 with sample 4× buffer
(17.4% sodium dodecyl sulphate, 7% sucrose, and phe-
nol red in Tris-HCl, pH 6.8). Sixteen microliters of sample
was added to the wells under non-reducing and non-
denaturing conditions. After electrophoresis, the gel was
washed twice with washing buffer, followed by a brief
rinsing in washing buffer with Triton X-100. The gel was
then placed in PBS, pH 7.4 containing 0.9 mmol CaCl2
and MgCl2 and incubated overnight at room temperature
on a moving platform. The next morning, the gel was
stained with Coomassie Brilliant Blue G250 (0.1% in
25% methanol and 10% acetic acid in water) and
destained in the same solution in absence of the dye.
Statistical analyses
Data are described as the mean ± standard deviation. For
Figure 1, each treatment was compared to its relative con-
trol using a Student t test. For Figures 2, 3, 4, and 5, treat-
ment effects were compared using ANOVA with
Bonferroni correction. The latter analysis does not apply
to Figure 6, but was used to analyze the data presented in
Figure 7. The data were analyzed using the SAS statistical
software package "SigmaPlot", version 9.0 (SAS Institute
Inc., Cary, North Carolina). The significance level was
established at P < 0.05. The quantitative data were pre-
sented as three repeats from one independent experiment.
This is representative of two independent experiments
with similar results.
Results
As2O3 and berberine inhibit the proliferation of C6 and U-
87 glioma cells
In the first instance, the effect of As2O3 and berberine,
applied separately or in combination, on the viability of
C6 rat glioma cells and U-87 human malignant glioma
cells was investigated. The cell proliferation was deter-
mined using the MTT assay performed with logarithmi-
cally growing glioma cells treated with As2O3  and
berberine (Figures 1A and 1B). Within 24 h of the addi-
tion of 5 µM As2O3 and 10 µM berberine alone on the C6
cells, proliferation was reduced to 78% and 88 %, respec-
tively (P < 0.05). Treatment with the same concentrations
of As2O3 or berberine did not elicit marked cytotoxic
effects on U-87 cells (Figure 1B). However, at a concentra-
tion of 20 µM, decreased cell viability was observed. Inter-
estingly, based on the trypan blue dye exclusion assay, it
was observed that 5 µM As2O3 and 10 µM berberine com-
bined treatment exhibited a minor effect on the viability
of C6 and U-87 cells (data not shown). A dose-dependent
effect on the inhibition of the C6 or U-87 glioma cell pro-
liferation at lower agent concentrations was observed
(Figure 1C). Co-treatment with 5 µM As2O3 and 10 µM
berberine, concentrations used for all further analyses, led
to an inhibition of the cell proliferation and indicated no
major signs of apoptosis, suggesting that another biologi-
cal or pharmacological function played a role.
Berberine enhances As2O3-mediated reduction in glioma 
cell migration and invasion
Using the scratch-wound assay, a continuous rapid move-
ment was observed for all cells, but a resultant movement
of a glioma cell migration front was clearly evident at 24
h, where a highly confluent (90%–100%) monolayer
region gradually migrated into the cell-free 'scratch' region
(Figure 2A). In the presence of 5 µM As2O3, migration was
significantly reduced after 12 and 24 h of incubation,
whereas co-treatment with 5 µM As2O3 and 10 µM berber-
ine led to a virtually complete inhibition of cell migration
(Figures 2A and 2B).
Cell proliferation and invasive behaviors are important
characteristics of cancer cells and indicators of malig-
nance, and both are targets of anti-cancer agent develop-
ment [44]. The Boyden chamber assay was used to
evaluate the inhibitory effect of combined treatment with
As2O3 and berberine on C6 or U-87 glioma cell migration
and invasiveness. The observations revealed that berber-
ine-As2O3 co-treatment resulted in a remarkable inhibi-
tion of glioma cell migration as compared to either
treatment alone (Figure 3), which supported the results
obtained with the scratch-wound assay (Figure 2). In
addition, co-treatment with As2O3  and berberine also
exhibited a significant anti-invasive effect on glioma cellsBMC Cancer 2008, 8:58 http://www.biomedcentral.com/1471-2407/8/58
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Evaluation of the cell viability of C6 glioma and human U-87 cells treated with berberine or As2O3, and co-treated with As2O3  and berberine for 24 h Figure 1
Evaluation of the cell viability of C6 glioma and human U-87 cells treated with berberine or As2O3, and co-
treated with As2O3 and berberine for 24 h. C6 glioma cells (A) and human U-87 cells (B) were incubated with 1, 2, 5, 10, 
and 20 µM berberine or As2O3 for 24 h and the proportion of surviving cells was determined using the MTT assay as described 
in Methods. (C) C6 glioma and human U-87 cells were co-treated with 5 µM As2O3 and 1, 2, 5, 10, and 20 µM berberine for 24 
h, and the cell growth was determined as described in Methods. Control cells were treated with As2O3 alone. The experiments 
were performed in triplicate and data are presented as means ± SD. * and ** indicate means that are significantly different 
when compared to the control group of C6 with P < 0.05 and P < 0.01, respectively. # and ## indicate means that are signifi-
cantly different when compared to the control group of U-87 with P < 0.05 and P < 0.01, respectively.
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Determination of the effects of berberine-As2O3 co-treatment on cell migration and growth using the scratch-wound assay Figure 2
Determination of the effects of berberine-As2O3 co-treatment on cell migration and growth using the scratch-
wound assay. C6 glioma cells were incubated with 5 µM As2O3 or 10 µM berberine alone and with 5 µM As2O3 and 10 µM 
berberine for 4, 12, and 24 h and the migration was visualized as described in Methods (A). The percentage of surface area 
filled by the C6 cells was subsequently quantified by densitometric analyses relative to that of the control which was set at 
100% as shown in the graph (B). Data are presented as means ± SD based on three independent experiments. * and ** indicate 
means that are significantly different when compared to the control group of 12 h incubation with P < 0.05 and P < 0.01, 
respectively. # and ## indicate means that are significantly different when compared to the control group of 24 h incubation with 
P < 0.05 and P < 0.01, respectively.
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Effect of berberine on As2O3-inhibited motility of C6 glioma and U-87 cells Figure 3
Effect of berberine on As2O3-inhibited motility of C6 glioma and U-87 cells. (A) Cells were incubated with 5 µM 
As2O3 or 10 µM berberine and co-treated with 5 µM and 10 µM berberine for 24 h. The lower and upper chemotaxis cells 
were separated by a polycarbonate membrane. Microscopy images detected cells that migrated into the inner membrane. Mag-
nification: ×200. The cell migration was quantified by counting the number of cells that migrated into the inner membrane (B). 
Control cells remained untreated. The experiments were performed in triplicate and data are presented as means ± SD. * and 
** indicate means that are significantly different when compared to the control group of C6 with P < 0.05 and P < 0.01, respec-
tively. # and ## indicate means that are significantly different when compared to the control group of U-87 with P < 0.05 and P 
< 0.01, respectively.
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Effect of berberine on As2O3-inhibited invasiveness of C6 glioma and U-87 cells Figure 4
Effect of berberine on As2O3-inhibited invasiveness of C6 glioma and U-87 cells. (A) Cells were incubated with 5µM 
As2O3 or 10 µM berberine and co-treated with 5 µM and 10 µM berberine for 24 h. Invasion through a layer of Matrigel was 
determined by a Boyden Chamber method as described in Methods. The invasiveness was quantified and is presented in the 
graph (B). Control cells remained untreated. The experiments were performed in triplicate and data are presented as means ± 
SD. * and ** indicate means that are significantly different when compared to the control group of C6 with P < 0.05 and P < 
0.01, respectively. # and ## indicate means that are significantly different when compared to the control group of U-87 with P < 
0.05 and P < 0.01, respectively.
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(Figure 4), which enhanced the dose-response relation-
ship.
An important characteristic of advanced cancer develop-
ment metastasis, during which cancer cells migrate to
other tissues and organs, is the rearrangement of the
cytoskeleton of migrating cells [45]. The cytoskeleton
changes in C6 glioma cells treated with 5 µM As2O3 or 10
µM berberine, and co-treated with As2O3 and berberine,
were visualized using F-actin specific antibodies that bind
to F-actin (filopodia; yellow arrow head, Figure 5), and
revealed structural rearrangements in the actin cytoskele-
ton that were observed upon cell spreading and ruffling
(Figure 5).
Berberine prevents cytosol-to-membrane translocation of 
PKCα and PKCε isoenzymes
Recent studies report that overexpressed or hyperactive
PKC is among the most distinguishing characteristics of
central nervous system tumors [46]. The PKCα and PKCε
activity levels seem to be increased in malignant gliomas
and mechanisms related to tumor cell invasion, and
metastasis is activated [47,48]. To further evaluate the
effect of chemotherapeutic agents such as As2O3 in the
Actin rearrangements in C6 glioma cells treated with As2O3 or berberine Figure 5
Actin rearrangements in C6 glioma cells treated with As2O3 or berberine. C6 glioma cells were incubated with 5 
µM As2O3 or 10 µM berberine and co-treated with 5 µM and 10 µM berberine for 24 h. Actin rearrangements were visualized 
by immunolocalization using anti-F-actin antibodies as described in Methods. Co-treatment with berberine and As2O3 resulted 
in actin (arrows) impolarization at the edges of the cell. Actin ruffing at the edges of the elongated cells was also observed and 
indicative of increased migration.
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Effect of berberine and As2O3 on the translocation of PKCα and PKCε Figure 6
Effect of berberine and As2O3 on the translocation of PKCα and PKCε. C6 glioma cells were incubated for 12 and 24 
h with 10 µM berberine (Ber) or 5 µM As2O3 (As), and with 10 µM berberine and 5 µM As2O3 (A+Ber) (A, B). Cytosolic (B) 
and membrane fractions (A) were evaluated for the presence of PKCα and PKCε by Western blotting. Control cells were not 
treated in the presence of 10% Fetal Calf Serum (FCS) (N10). Cells that were not exposed to agents were used as negative 
control in the presence of 1% FCS (N1). The PKC levels in the respective fractions were quantified and normalized taking the 
β-actin value as a loading control as presented in the graph. Each value is the relative ratio of PKCs membrane to cytosol frac-
tion (presumably, the ratio of untreated control is 1). In addition, the nuclear protein fractions were evaluated for the presence 
of myc and c-jun, two transcription factors that act downstream of PKC, by Western blotting (C). The quantitative data were 
presented as three repeats from one independent experiment and indications are in panel A. The intensity of the protein bands 
was quantified and the level relative to the N10 control band was presented (fold).
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Berberine and As2O3 inhibit the phosphorylation of ERK and decrease the ornithine decarboxylase (ODC), MT1-MMP, and  MMP2 protein levels Figure 7
Berberine and As2O3 inhibit the phosphorylation of ERK and decrease the ornithine decarboxylase (ODC), 
MT1-MMP, and MMP2 protein levels. C6 glioma cells were incubated for 24 h with 10 µM berberine (Ber) or 5 µM As2O3 
(As), and with 10 µM berberine and 5 µM As2O3 (A+Ber). Total cell lysates were prepared and subjected to Western blot anal-
ysis. Protein levels of phosphorylated ERK1/ERK2 and non-phosphorylated ERK1/ERK2, and ODC, MT1-MMP and MMP2 were 
detected using the respective monoclonal antibodies (A). The condition serum free media were collected for gelatin zymogra-
phy analysis from C6 glioma and U-87 cells. Determined activities of these proteins were subsequently quantified by densito-
metric analysis with the value of controls set at 100% as shown in the graph. The quantitative data were presented as the mean 
of three repeats from one independent experiment. Other data in this figure is presented as mean ± SD of three independent 
experiments. * and ** indicate means that are significantly different when compared to the control group of C6 with P < 0.05 
and P < 0.01, respectively. # and ## indicate means that are significantly different when compared to the control group of U-87 
with P < 0.05 and P < 0.01, respectively.
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PKC signaling pathway, we examined whether berberine
enhanced As2O3-mediated modulation of the transloca-
tion of PKCα and PKCε isoenzymes using Western blot
analyses. Remarkably, 10 µM berberine had a dramatic
effect on the cytosol-to-membrane translocation of PKCα
and PKCε after 12 and 24 h incubation (Figures 6A and
6B). Furthermore, the combined treatment with As2O3
and berberine resulted in inhibition of the activation of
PKCα and PKCε, but not PKCδ (Figures 6A and 6B), as
compared to the negative control (1% fetal calf serum).
Once activated, PKC can transmit signals to the nucleus
via MAPK-mediated cascades and activated ERKs can
induce the production of transcription factors including
myc and jun [49,50]. To further investigate the effect of
As2O3-berberine co-treatment on PKC-mediated signal-
ing, the nuclear levels of those transcription factors were
determined. Figure 6C illustrates that the levels of myc
and jun in nuclei were significantly reduced after treat-
ment with 10 µM berberine in the presence of 5 µM As2O3
for 24 h.
Inhibitory effect of berberine and A2O3 on the activation of 
MMP-2 associated with invasiveness of glioma cells via 
interference with PKCs
Activated PKCs enable the expression of genes encoding
enzymes that are involved in cell proliferation and inva-
sion [30,46,50] such as the gene encoding ornithine
decarboxylase (ODC), an enzyme that plays a role in cell
transformation and excessive extracellular matrix degrada-
tion [51]. Because the observations presented above
strongly suggest that berberine and As2O3 act via the inhi-
bition of PKC signaling, the activation of three PKC-
dependent key factors was examined by Western blot
analyses. These experiments demonstrated that the ber-
berine-As2O3-mediated enhanced suppression of ERK
phosphorylation led to a decrease of the levels of ODC,
MT1-MMP, and MMP-2 in C6 glioma cells to values that
resembled those observed in negative controls (Figure
7A).
Extracellular matrix breakdown is pivotal for cellular inva-
sion, indicating that matrix-degrading proteinases are
essential for tumor cell metastasis [28]. Therefore, we
determined the activity of MMP-2 by gelatin zymography
after 24 h incubation with 5 µM As2O3 and 10 µM berber-
ine in C6 or U-87 glioma cells. A significant decrease in
the activity of MMP-2 was observed after 24 h exposure to
As2O3 and berberine (Figure 7B), likely explaining why
co-treatment with berberine and As2O3 strongly affects gli-
oma cell migration and invasiveness.
Discussion
Berberine is a naturally occurring alkaloid that exhibits
various pharmacological effects. Clinical trials and studies
in animal model systems have demonstrated that berber-
ine has anti-microbial, vulnerary, cardiovascular [52],
immunostimulatory, anti-hemorrhagic, and anti-inflam-
matory properties, as well as selective repression of the
growth of several carcinoma cells without causing cytotox-
icity in the liver [32,53]. Control experiments using rat
primary cortical astrocytes illustrated that treatment with
5 µM As2O3 or 20 µM berberine, or co-treatment with 5
µM As2O3 and 20 µM berberine, did not cause any detect-
able toxic effects (data not shown). However, the effect of
berberine on migration and invasion of glioma cells at rel-
atively low concentrations was striking, particularly in the
presence of As2O3. Most interesting was the enhanced
effect that As2O3-berberine co-treatment had on glioma
cell migration and invasiveness, as 10 µM berberine sig-
nificantly lowered the concentration of As2O3 required to
obtain an antiproliferation effect on human glioma cells.
This dose-lowering effect, unique to this study, could not
be exploited in other studies in which tumor cells were
treated with either berberine [37,38] or As2O3 [14].
As2O3  has considerable efficacy in the treatment of
relapsed APL, inducing partial differentiation and pro-
moting apoptosis of malignant promyelocytes [54,55].
The mechanisms underlying As2O3-mediated apoptosis
are only beginning to be understood, but appear to be dis-
tinct from those employed by traditional cytotoxic agents.
The intracellular glutathione redox system represents the
best-characterized mechanism of As2O3  sensitivity
[39,55]. These findings underscore the importance of
understanding how differences in cell types or cellular
environments might affect the action of As2O3. A determi-
nation of the factors that mediate sensitivity to As2O3 will
allow the use of this agent in such a way as to optimize
therapeutic outcomes and minimize toxicity in the treat-
ment of various malignancies. To date, evidence that the
development of resistance to chemotherapy affects the
response to arsenic is scarce. Thus, As2O3 represents a
novel chemotherapeutic agent worth for continuous
investigation, particularly when used in combination
with another agent such as berberine that exhibits an
enhanced inhibitory effect, which allows lowering the
working As2O3 concentration.
In previous studies, cell movement through tissue has
been observed to play a primary role in cancer progres-
sion. This process requires a series of distinct, but con-
certed, biological events in which the actin cytoskeleton
plays an essential role. These events include tumor cell
attachment to extracellular matrix (ECM) components,
and the degradation of the matrix by tumor cell-associ-
ated proteases [28,56]. It has long been known that in
most cell types, one or more PKC isoforms influence the
morphology of the F-actin cytoskeleton and overex-
pressed or hyperactive PKC is among the most distin-
guished characteristics of malignant central nervousBMC Cancer 2008, 8:58 http://www.biomedcentral.com/1471-2407/8/58
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system tumors including C6 or U-87 glioma cells [46,57].
In certain tumors, a reduction in PKCα and PKCε expres-
sion merely results in growth inhibition, so that a cyto-
toxic effect requires induction of apoptosis through
activation of PKCδ [58]. Exposure of C6 cells in the pres-
ence of As2O3 to berberine exhibits a significant effect
characterized by alterations in cell shape and actin
cytoskeleton changes. Moreover, the data presented
herein suggests that the cytosol-to-membrane transloca-
tion of PKCα and PKCε is slightly suppressed by As2O3,
and this inhibition is enhanced upon co-treatment with
berberine for 24 h, although berberine itself did cause
inactivation of PKCα and PKCε but not PKCδ. Similar to
the action of the PKC signaling pathway, the expression
on myc, c-fos, ODC, MT1-MMP, and MMP-2 as well as the
phosphorylation of ERK by co-treatment could be abol-
ished.
Arsenic-containing compounds have been used for the
treatment of cancer for hundreds of years in both tradi-
tional Chinese and Western medicine [59]. Only a few
reports are available that describe the underlying mecha-
nisms of the action of specific chemotherapeutic agents
used to treat cancer metastasis. In this study, we demon-
strate for the first time that berberine sensitizes malignant
glioma cells for As2O3-mediated suppression of migration
and invasiveness likely via decreased PKC signaling and
MMP-2 activation in the extracellular matrix. The involve-
ment of PKC signaling is not yet undoubtedly proven, as
the effect of As2O3 and berberine on glioma tumor cells
overexpressing PKCα and PKCε remains to be investi-
gated. Furthermore, we tried to investigate the dual effect
that berberine has on glioma cells. First, berberine exhib-
its an anti-oxidant activity thereby protecting healthy cells
against the As2O3-induced production of toxic reactive
oxygen species [5,33,53]. Second, berberine may reduce
the As2O3-mediated carcinogenic effect by inhibiting
PKCα translocation in the mouse epidermal JB6 cells [60].
This dual effect is particularly important in a co-treatment
with As2O3 because As2O3 is a carcinogen [10]; however,
upon co-treatment with berberine, the working concen-
tration of As2O3 can be significantly lowered, while, in
addition, healthy cells are protected against possible
adverse side effects caused by exposure to As2O3.
Invasion and metastasis inhibitors are effective (alone or
in combination therapy with other agents) in restraining
new tumor formation when earlier therapy or surgery has
failed. Therefore, it appears that a combination of As2O3
and berberine inhibits the proliferation and invasion of
glioma cells. Although future studies are required to
experimentally link the various pathways that appear to
be involved in the berberine/As2O3-mediated suppression
of glioma cell migration and invasiveness, to better under-
stand the molecular mechanisms that occur in the extra-
cellular matrix surrounding glioma cells during tumor
metastasis, to investigate novel methods to specifically
deliver, for instance, berberine and As2O3 to glioma tumor
cells, and to investigate the effectiveness and safeness of
berberin-As2O3  co-treatment in a clinical setting, this
study forms the basis for the design of novel therapeutic
strategies to ameliorate and prevent human glioma for-
mation. Furthermore, the observations presented herein
suggest that (i) berberine should be further considered as
a complementary antitumor treatment in clinical applica-
tions, and (ii) application of berberine has a dual amelio-
rating effect as it enhances the antitumor effect of As2O3
while it allows a lower working concentration of As2O3 by
which its global carcinogenic effect to healthy cells, medi-
ated by the fact that elemental arsenic can enter the cere-
brospinal fluid [61], is diminished.
Conclusion
We demonstrate that berberine enhances inhibition of the
migration and invasiveness of glioma cells mediated by
As2O3, or, in other words, that a concentration as low as
10 µM of the natural compound berberine is sufficient to
significantly lower the As2O3 concentration needed to
obtain its antiproliferation effect in a rat and human
malignant glioma cell line. While not yet undoubtedly
proven, our results suggest that this effect is likely medi-
ated by the disturbance in PKC signaling which leads to a
reduction of the level of MMP-2, a metalloprotease
involved in cancer cell migration during metastasis.
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